Table 1.
Characteristics of the included clinical trials in this study
| Study | Location | Study design |
Sample size (n) |
Sex (M/F) (n) |
Age (yrs) | HBeAg(+)/(-) (n) |
LAM-resistance mutations at baseline (LAM+ADV) / ETV (n) |
Regimen | Therapy period LAM+ADV vs. ETV |
Baseline ALT (IU/L) LAM+ADV vs. ETV |
HBVDNA level LAM+ADV vs. ETV |
The detection limit of HBV DNA |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAM +ADV |
ETV | LAM +ADV |
ETV | LAM+ADV vs. ETV |
LAM +ADV |
ETV | LAM+ADV | ETV | ||||||||
| Pellicelli 2009 | Italy | RCTs | 20 | 42 | NA | NA | Mean (SD): 47 (11) vs. 48 (9) |
NA (NS) | NA | LAM 100 mg/d + ADV 10 mg/d |
1.0 mg/d | 48 weeks vs. 48 weeks |
NA | Mean (SD) (log10 IU/ml): 5 (1.0) vs. 4.63 (1.3) |
NA | |
| Qiu 2009 |
China | RCTs | 30 | 30 | NA | NA | NA | 15/15 | 16/14 | NA | LAM 100 mg/d + ADV 10 mg/d |
1.0 mg/d | 48 weeks vs. 48 weeks |
Mean (SD): 141.1 (58.2) vs. 145.7 (61.9) |
Mean (SD) (log10 copies/ml): 7.78 (2.62) vs.7.82 (2.32) |
< 500 copies/ml |
| Ryu 2010 |
Korea | RCTs | 47 | 45 | 34/13 | 38/7 | Median (rang): 47 (20-68) vs. 41 (21-60) |
39/8 | 42/3 | M204I:14/15; L180M:1/0; M204I+M204V:0/1; M204I+L180M:8/9 M204V+L180M:14/13 M204I+M204V+L180M:10/7 |
LAM 100 mg/d + ADV 10 mg/d |
1.0 mg/d | Median (rang), months: 12 (12-24) vs. 15 (12-27) |
Median (range): 143 (26-1096) vs. 102 (17-677) |
Median (rang) (log10 copies/ml): 7.61 (5.19-9.46) vs.7.10 (5.43-9.47) |
< 300 copies/ml |
| Kim 2010 |
Korea | Cohort | 36 | 24 | 25/11 | 21/3 | Mean (SD): 46.8 (10.4) vs. 46.9 (8.7) |
20/16 | 18/6 | M204I or M204I+L180M: 24/11 M204V+L180M: 12/13 |
LAM 100 mg/d + ADV 10 mg/d |
1.0 mg/d | 24 months vs.24 months |
Mean (SD): 227.6 (267.8) vs. 136.3 (134.2) |
Mean (SD) (log10 copies/ml): 6.43 (1.40) vs. 6.51 (1.54) |
< 300 copies/ml |
| Lee 2010 |
Korea | Cohort | 48 | 33 | NA (NS) | NA (NS) |
NA (NS) | 41/7 | 30/3 | NA | LAM 100 mg/d + ADV 10 mg/d |
1.0 mg/d | 96 weeks vs. 96 weeks |
NA (NS) | NA (NS) | < 140 copies/ml |
| Chung 2011 | Korea | Cohort | 44 | 52 | 35/9 | 33/19 | Mean (SD): 53.7 (10.5) vs. 50.0 (10.4) |
26/18 | 33/19 | M204V+ L180M: 18/21 M204I+ L180M: 9/9 M204V/I+ L180M: 2/5 M204I: 14/17 M204V/I+ L180M+ V173L: 1/0 |
LAM 100 mg/d + ADV 10 mg/d |
1.0 mg/d | 48 weeks vs. 48 weeks |
Mean (SD): 151 (125) vs. 193 (185) |
Mean (SD) (log10 IU/ml): 6.86 (1.17) vs. 6.81 (1.03) |
< 50 IU/ml |
NA: not available; NS: not significant; iLAM: lamivudine; ADV: adefovir; ETV: entecavir; SD: Standard Deviation; RCTs: randomized controlled trials.